Semaglutide Market Faces Slump with ₹100 Crore Excess Inventory
The meteoric rise of the semaglutide weight-loss therapy market in India has hit an unexpected roadblock. Following a massive surge driven by generic competition, the industry is now grappling with a significant inventory overhang that could impact pharmaceutical margins.
The Surge and Subsequent Slowdown
The obesity therapy market, currently valued at approximately ₹2,000 crore, experienced an extraordinary explosion in April. Following the patent expiry of semaglutide on March 20, a flood of cheaper generic brands from major players like Sun Pharma, Dr. Reddy's, and Torrent Pharmaceuticals entered the market. This led to a massive 50% month-on-month growth in value and an 88% jump in volumes during April.
However, this momentum failed to carry over into May. According to data from market research firm Pharmarack, month-on-month value growth slowed sharply to just 6%, while unit growth decelerated to 12%. This sudden moderation has left the supply chain struggling to balance the sudden influx of products with actual market demand.
Inventory Overhang Hits ₹100 Crore
The primary concern for industry stakeholders is the massive buildup of unsold stock within the trade channel. Rajiv Singhal, General Secretary of the All India Organisation of Chemists and Druggists (AIOCD), reported that stockists and wholesalers are currently holding between 50 to 60 days of semaglutide inventory. This is significantly higher than the industry standard of 30 to 45 days.
Industry estimates suggest that this excess stock sitting in the trade channel is worth approximately ₹100 crore. Consequently, many channel partners have halted fresh procurement from pharmaceutical manufacturers until the current surplus is liquidated, creating a bottleneck in the supply chain.
Regulatory Hurdles and Competitive Landscape
Industry executives suggest that the cooling demand might not be purely organic. The slowdown may be linked to government advisories and stricter prescribing guidelines introduced in April. These guidelines mandate that GLP-1 receptor agonists—the class of drugs containing both semaglutide and tirzepatide—should only be prescribed by qualified specialists, which may be tempering the rapid "off-label" adoption for weight loss.
Despite the semaglutide slowdown, Eli Lilly’s Mounjaro (tirzepatide) remains a powerhouse in the sector. Mounjaro continued to lead the therapy segment in May, with sales rising by 12% to reach ₹136 crore. While the semaglutide segment recalibrates, the broader organized pharma retail market remains resilient, growing by nearly 11% in May, largely supported by chronic disease therapies.
Key Takeaways
- Inventory Crisis: The semaglutide trade channel is currently saddled with nearly ₹100 crore in excess stock, with wholesalers holding up to 60 days of inventory.
- Growth Moderation: After an April surge of 50% in value, May saw growth plummet to just 6%, leading to a freeze in fresh procurement from manufacturers.
- Regulatory Impact: Stricter guidelines requiring specialists to prescribe GLP-1 therapies are believed to be a contributing factor to the recent slowdown in sales.